ArticleJournal of ophthalmic inflammation and infection2025
Scleritis in Iran.
Article in Journal of ophthalmic inflammation and infection, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo present the demographic and clinical presentations of anterior scleritis among Iranian patients.
methodsThis retrospective case-series at a tertiary center in Iran, identified and analyzed anterior scleritis cases admitted from 2008 to 2018. Extracted data included demographics, clinical features, background systemic diseases, utilized therapies, and follow-up data on visual outcomes, ocular complications, and recurrence rate. Patients with incomplete records were excluded from the analysis.
resultsSixty-five patients (83 eyes) with anterior scleritis were included, with a female predilection (77%) and a mean age (± SD; range) of 44.8 (± 14.6; 11-81). Diffuse and necrotizing scleritis were the most and least common subtypes, respectively. Bilateral involvement (28% at baseline, 44.6% eventually) and concurrent keratitis (10.7%) or uveitis (16.9%) were documented in some cases. Most cases were idiopathic (61.5%). Scleritis was the initial manifestation of autoimmune diseases in six patients. In addition to oral and/or intravenous corticosteroid therapy, most of our patients (70.7%) were treated with immunosuppressive regimens. No inter-subtype difference was noted in recurrence rate and time to treatment cessation. Necrotizing subtype was associated with worse visual outcomes and more frequent ocular complications.
conclusionDespite limitations in data collection and follow-up, our findings contribute valuable insights into the clinical characteristics and management of scleritis in a group of Iranian patients for the first time.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.